Thanks Biowatch. CRISPR should remove that risk as the only thing that integrates is the repair template which theoretically only targets the defective gene that has been cut by the CRISPR machinery. I believe either NTLA or CRSP uses liposomes to get the CRISPR proteins, guide RNA and the repair template DNA into cells, which removes the risk of the DNA from the CRISPR encoding genes from integrating somewhere in the genome. I must point out that there could be unintended off-target effects so risk isn't zero but should be far less than using virus as a lentivirus or retroviral vector.
FYI, I don't own either NTLA or CRSP, at least not yet as I haven't looked into them in any detail.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.